CRBU Insider Trading

Insider Ownership Percentage: 9.50%
Insider Buying (Last 12 Months): $45,051.20
Insider Selling (Last 12 Months): $4,811.40

Caribou Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Caribou Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Caribou Biosciences Share Price & Price History

Current Price: $0.94
Price Change: Price Increase of +0.148 (18.73%)
As of 04/9/2025 03:44 PM ET

This chart shows the closing price history over time for CRBU up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$0.79Closing price on 04/08/25:

Caribou Biosciences Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Caribou Biosciences (NASDAQ:CRBU)

77.51% of Caribou Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CRBU by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$236kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal InflowsTotal Outflows
Caribou Biosciences logo
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Read More on Caribou Biosciences

Today's Range

Now: $0.94
Low: $0.77
High: $0.97

50 Day Range

MA: $1.13
Low: $0.76
High: $1.46

52 Week Range

Now: $0.94
Low: $0.66
High: $4.59

Volume

798,551 shs

Average Volume

1,579,031 shs

Market Capitalization

$87.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.36

Who are the company insiders with the largest holdings of Caribou Biosciences?

Caribou Biosciences' top insider shareholders include:
  1. Rachel E Haurwitz (CEO)
  2. Barbara G Mcclung (Insider)
  3. Sriram Ryali (CFO)
Learn More about top insider investors at Caribou Biosciences.

Who are the major institutional investors of Caribou Biosciences?

Caribou Biosciences' top institutional shareholders include:
  1. Green Alpha Advisors LLC — 0.46%
Learn More about top institutional investors of Caribou Biosciences stock.

Which institutional investors are buying Caribou Biosciences stock?

During the last quarter, CRBU stock was acquired by institutional investors including:
  1. Green Alpha Advisors LLC
During the last year, these company insiders have bought Caribou Biosciences stock:
  1. Rachel E Haurwitz (CEO)
  2. Barbara G Mcclung (Insider)
Learn More investors buying Caribou Biosciences stock.